<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03533101</url>
  </required_header>
  <id_info>
    <org_study_id>HE18-00010</org_study_id>
    <nct_id>NCT03533101</nct_id>
  </id_info>
  <brief_title>Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation</brief_title>
  <official_title>Tocilizumab for Cytokine Release Syndrome Prophylaxis in Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tocilizumab will be administered prior to transplantation in order to prevent the onset of
      cytokine release syndrome and its complications associated to peripheral blood haploidentical
      hematopoietic stem cell transplantation with post-transplant cyclophosphamide
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytokine release syndrome (CRS) is a common and potentially severe toxicity associated to
      haploidentical peripheral blood (PBSC) hematopoietic stem cell transplantation (Haplo-HSCT),
      which was described previously in the context of immunotherapies for acute lymphoblastic
      leukemia such as chimeric antigen receptor T-cells and blinatumomab.

      CRS is characterized by immune system activation with a high level of circulating
      inflammatory cytokines including IL-6. Haplo-HSCT recipients have a high incidence of
      post-transplant fever, with elevated IL-6 in absence of documented infection. CRS occurs more
      frequently when using PBSC, and severe cases have been associated to delayed engraftment,
      increased transplant-related mortality and lower survival.

      Tocilizumab an IL-6 receptor-targeted monoclonal antibody has been effectively used to treat
      CRS in several scenarios, including Haplo-HSCT. Therefore, there is considerable interest for
      the development of a successful strategy for CRS prevention with tocilizumab, potentially
      eliminating complications. However, it is currently unknown whether the use of this
      monoclonal antibody can adversely affect the outcome of Haplo-HSCT recipients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2018</start_date>
  <completion_date type="Anticipated">June 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Adaptive design using two different doses of tocilizumab prophylaxis</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine release syndrome</measure>
    <time_frame>1 week</time_frame>
    <description>Incidence of fever in the first seven days after haploidentical transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization rate</measure>
    <time_frame>1 week</time_frame>
    <description>Incidence of hospitalization in the first seven days after haploidentical transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>1 week</time_frame>
    <description>According to Common Terminology Criteria for Adverse Events v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 concentration</measure>
    <time_frame>1 week</time_frame>
    <description>Concentration of serum IL-6 prior and during the first week after transplantation|</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cytokine Release Syndrome</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>Tocilizumab 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab 4 mg/kg IV single dose day -1 prior to haploidentical transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab 8 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tocilizumab 8 mg/kg IV single dose day -1 prior to haploidentical transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome</description>
    <arm_group_label>Tocilizumab 4 mg/kg</arm_group_label>
    <arm_group_label>Tocilizumab 8 mg/kg</arm_group_label>
    <other_name>Actemra</other_name>
    <other_name>RoActemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Haploidentical transplant recipients

          -  Informed consent signature

          -  Previous diagnosis of any neoplastic, metabolic or autoimmune disease

        Exclusion Criteria:

          -  History of immune deficiency virus infection

          -  Hepatitis C or B virus infection

          -  Documented bacterial of fungal infection prior to tocilizumab infusion

          -  Previous use of tocilizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gómez-Almaguer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario &quot;Dr. José Eleuterio González&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>César H Gutiérrez-Aguirre, MD</last_name>
    <phone>+528183486136</phone>
    <phone_ext>435</phone_ext>
    <email>hematohu@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Perla R Colunga-Pedraza, MD</last_name>
    <phone>+528183488510</phone>
    <phone_ext>378</phone_ext>
    <email>colunga.perla@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose E Gonzalez UANL</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>César H Gutiérrez-Aguirre, MD</last_name>
      <phone>52 8183488510</phone>
      <email>hematohu@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Oscar O Márquez-Pinedo, MD</last_name>
      <phone>52 8115273932</phone>
      <email>omp0287@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Gomez-Almaguer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016 Jul;8(8):959-70. doi: 10.2217/imt-2016-0020. Review.</citation>
    <PMID>27381687</PMID>
  </reference>
  <reference>
    <citation>Teachey DT, Grupp SA. Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Oct;22(10):1736-1737. doi: 10.1016/j.bbmt.2016.08.010. Epub 2016 Aug 16.</citation>
    <PMID>27543158</PMID>
  </reference>
  <reference>
    <citation>Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 Apr 19. pii: S1083-8791(18)30191-5. doi: 10.1016/j.bbmt.2018.04.010. [Epub ahead of print]</citation>
    <PMID>29680516</PMID>
  </reference>
  <results_reference>
    <citation>Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R. Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. Biol Blood Marrow Transplant. 2016 Oct;22(10):1851-1860. doi: 10.1016/j.bbmt.2016.06.010. Epub 2016 Jun 16.</citation>
    <PMID>27318038</PMID>
  </results_reference>
  <results_reference>
    <citation>Kennedy GA, Varelias A, Vuckovic S, Le Texier L, Gartlan KH, Zhang P, Thomas G, Anderson L, Boyle G, Cloonan N, Leach J, Sturgeon E, Avery J, Olver SD, Lor M, Misra AK, Hutchins C, Morton AJ, Durrant ST, Subramoniapillai E, Butler JP, Curley CI, MacDonald KP, Tey SK, Hill GR. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014 Dec;15(13):1451-9. doi: 10.1016/S1470-2045(14)71017-4. Epub 2014 Nov 14.</citation>
    <PMID>25456364</PMID>
  </results_reference>
  <results_reference>
    <citation>Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 Apr;103(4):717-727. doi: 10.3324/haematol.2017.183434. Epub 2018 Jan 19.</citation>
    <PMID>29351985</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>David Gomez Almaguer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Tocilizumab</keyword>
  <keyword>Haploidentical</keyword>
  <keyword>Peripheral blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

